FinBERT, a financial-language model, scores this headline as positive (78% confidence). That is the news tone only — not the full stock rating.
Stocks › QURE
Uniqure N.V. (QURE) stock analysis
SKIP 6% confidence · analysed Nov 2, 2026
On Nov 2, 2026, our model rated Uniqure N.V. (QURE) SKIP with 6% confidence at a price of $24.83. That means the signals cancel out; the model sees no clear edge either way.
Analysed price$24.83
Technical picture
The 14-day RSI is 65, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is about normal (1.1x the 20-day average).
Fundamentals
The company reports a profit margin of 0.0% and revenue growth of +11.0%.
In its latest quarter it earned $-1.07 per share, which missed the $-0.71 analysts expected, with revenue +11.0% year over year.
Wall Street's average rating is 1.4 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $60.44.
The next earnings report is expected around Nov 4, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.06 (SKIP). Technicals: RSI 64.77, MACD bullish, price below SMA50. Fundamentals: margin 0.0%, revenue growth 11.0%. Financial results: YoY revenue +11.0%, last EPS surprise -50.7%, next earnings 2026-11-04. FinGPT news read: positive. Reference price $24.83; no trade levels (SKIP).
Past ratings for QURE
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 2, 2026 | SKIP | 6% | $24.83 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on QURE
Nov 2, 2026 · uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease
- Nov 2, 2026: uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease (GlobeNewswire)
Frequently asked questions
Is QURE a buy right now?
As of Nov 2, 2026, our automated model rates Uniqure N.V. (QURE) SKIP with 6% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Uniqure N.V. report earnings next?
The next earnings report is expected around Nov 4, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.